Home > Healthcare > Medical Devices > Diagnostic Devices > Meningitis Diagnostic Testing Market

Meningitis Diagnostic Testing Market Share

Report ID: GMI11874
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Meningitis Diagnostic Testing Market Share

The meningitis diagnostic testing industry is marked by a highly competitive landscape, characterized by rapid innovation and technological progress. Prominent pharmaceutical companies hold a significant share of the market, driven by their extensive portfolios of diagnostics tests and advanced treatment options. Strategic initiatives, such as mergers, acquisitions, and collaborations, further strengthen the market position of key players, allowing them to expand the product offerings and access new markets.

Meningitis Diagnostic Testing Market Companies

Prominent players operating in the meningitis diagnostic testing industry include:

Abbott Laboratories
Becton, Dickinson and Company
Biomerieux
Bio-Rad Laboratories
Certest Biotec
ELITechGroup
F. Hoffmann-La Roche
IMMY
Seegene
Siemens Healthineers
Thermo Fisher Scientific
Uniogen

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of meningitis diagnostic testing reached USD 119.5 million in 2023 and is set to grow at a 3.5% CAGR from 2024 to 2032, driven by the increasing global prevalence of meningitis cases.

The PCR assay segment dominated the market with USD 42.2 million in 2023 due to its superior accuracy, sensitivity, and speed in detecting genetic material of pathogens directly from cerebrospinal fluid samples.

The North America market is expected to grow at a 3.3% CAGR, reaching USD 73.7 million by 2032, led by advanced healthcare infrastructure and rising awareness about meningitis.

The leading companies in the industry include Abbott Laboratories, Becton, Dickinson and Company, Biomerieux, Bio-Rad Laboratories, Certest Biotec, ELITechGroup, F. Hoffmann-La Roche, IMMY, Seegene, Siemens Healthineers, Thermo Fisher Scientific, and Uniogen.